Qiming Venture Partners and Quan Capital have led a USD 120m Series B round for OriCell Therapeutics, a China-based drug developer that is working on CAR-T cell therapies that target cancer.
Shanghai STVC Group, Jianyi Capital (formerly Sinopharm Capital), a fund-of-funds linked to the Suzhou city government, and Boquan Equity Investment Management also took part, alongside unnamed foreign...
Black Sesame Technologies, a China-based chipmaker specializing in autonomous driving applications, has closed a Series C extension led by SummitView Capital. This brings the size of the overall round to USD 500m.
Japanese lower middle-market private equity firm J-Star has made an investment of undisclosed size in air cargo transportation and courier services provider Score Japan Holdings.
Gaorong Capital and Tsing Song Capital have led a CNY 500m (USD 74m) Series C for IntellectiveBio, a China-based contract development and manufacturing organisation (CDMO).
Morningside Venture Capital has teamed up with Kingray Capital, Trinity Innovation Fund, TigerYeah Capital, and FountainBridge Capital to provide USD 20m in angel and pre-Series A funding for Epigenic Therapeutics, a China-based gene editing specialist.